OOIR: Observatory of International Research

Papers

(The H4-Index of International Journal of Drug Policy is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Publisher's Note	273
Editorial Board	103
Older age at smoking initiation predicts successful cessation in adults who smoke: A prospective study	72
Incarceration history, antiretroviral therapy, and stigma: A cross-sectional study of people with HIV who inject drugs in St. Petersburg, Russia	70
Opioid prescribing restrictions and opioid use among the Louisiana Medicaid population	64
Doing more with less: A proposal to advance cigarette packaging regulations in the United States	59
Editorial Board	57
Editorial Board	57
Editorial Board	55
Co-designing the INHSU Prisons Hepatitis C Advocacy Toolkit using the Advocacy Strategy Framework	52
A content analysis of cannabis edibles package marketing in the United States	50
Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare	47
Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts	46
Editorial Board	45
Ecological dimensions of cannabis regulation in the Rif, Morocco	44
The social-structural contexts of cannabis consumption and harm reduction among young Nigerian women	43
Quasi-experimental study on the impact of local smoke-free policies on smoking among Indonesian adults: Evidence from repeated national health surveys	42
Increased solitary drug use during COVID-19: An unintended consequence of social distancing	41
A comprehensive analysis of jurisdiction-specific laws related to scheduling or required prescription drug monitoring of gabapentin in the United States, 2016–2024	41
Contentious legality in decentralized governance: The rise and decline of cannabis social clubs in Spain	40
Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States	40
Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis	38
Leveraging pooled medical examiner records to surveil complex and emerging patterns of polysubstance use in the United States	38
Barriers to evidence-based alcohol policies in France: Insights from interviews with parliament members	37
International property rights for Cannabis landraces and terroir products. The case of Moroccan Cannabis and hashish	37

Impact of health policies on opioid tapering and discontinuation among patients receiving long-term opioid therapy for chronic noncancer pain	36
Bridging the gap: An environmental scan of post-overdose program features and evaluation measures	36
The introduction of fentanyl on the US–Mexico border: An ethnographic account triangulated with drug checking data from Tijuana	35
‘Choice’ of social media platform or encrypted messaging app to buy and sell illegal drugs	35
Social-spatial network structures among young urban and suburban persons who inject drugs in a large metropolitan area	35
Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers	34
Trends in the use of cannabis products in Canada and the USA, 2018 – 2020: Findings from the International Cannabis Policy Study	34
Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada	34
Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia	33